These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 11317184)

  • 1. Treatment of stage I hypertension and development of renal dysfunction.
    Bakris GL
    J Hum Hypertens; 2001 Feb; 15(2):81-4. PubMed ID: 11317184
    [No Abstract]   [Full Text] [Related]  

  • 2. [Treatment of hypertension during the course of kidney diseases].
    Wiecek A
    Przegl Lek; 1997; 54(11):773-6. PubMed ID: 9501687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hypertension and renal disease].
    Kamper AL; Pedersen EB; Strandgaard S
    Ugeskr Laeger; 2009 Jun; 171(25):2109-13. PubMed ID: 19671393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does treatment of non-malignant hypertension reduce the incidence of renal dysfunction? A meta-analysis of 10 randomised, controlled trials.
    Hsu CY
    J Hum Hypertens; 2001 Feb; 15(2):99-106. PubMed ID: 11317188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood pressure and renal function: therapeutic implications.
    Ruilope LM; Campo C; Rodriguez-Artalejo F; Lahera V; Garcia-Robles R; Rodicio JL
    J Hypertens; 1996 Nov; 14(11):1259-63. PubMed ID: 8934351
    [No Abstract]   [Full Text] [Related]  

  • 6. Should reducing nocturnal blood pressure be a therapeutic target in CKD? The time is ripe for a clinical outcomes trial.
    Rahman M; Appel LJ
    Am J Kidney Dis; 2007 Dec; 50(6):901-3. PubMed ID: 18037089
    [No Abstract]   [Full Text] [Related]  

  • 7. Hypertension and the kidney: new avenues for an improved management of hypertension in renal diseases: introduction.
    Burnier M
    Semin Nephrol; 2007 Sep; 27(5):509-10. PubMed ID: 17868786
    [No Abstract]   [Full Text] [Related]  

  • 8. Aggressive blood pressure lowering is dangerous: the J-curve: con side of the arguement.
    Verdecchia P; Angeli F; Mazzotta G; Garofoli M; Reboldi G
    Hypertension; 2014 Jan; 63(1):37-40. PubMed ID: 24336630
    [No Abstract]   [Full Text] [Related]  

  • 9. Aggressive blood pressure lowering is dangerous: the J-curve: pro side of the arguement.
    Mancia G; Grassi G
    Hypertension; 2014 Jan; 63(1):29-36. PubMed ID: 24336629
    [No Abstract]   [Full Text] [Related]  

  • 10. Improvement of blood pressure control in hypertensive patients with renal diseases.
    Ohta Y; Tsuruya K; Fujii K; Tokumoto M; Kanai H; Matsumura K; Tsuchihashi T; Hirakata H; Iida M
    Hypertens Res; 2007 Apr; 30(4):295-300. PubMed ID: 17541207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antihypertensive treatment in kidney diseases: whom, with what, how intensively?].
    Ritz E; Heidland A; Nowack R; Rambausek M
    Dtsch Med Wochenschr; 1990 Aug; 115(35):1325-8. PubMed ID: 2202580
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of hypertension based on measurement of blood pressure variability: lessons from animal studies.
    Su DF
    Curr Opin Cardiol; 2006 Sep; 21(5):486-91. PubMed ID: 16900013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is renal antiaging possible?
    Ito S
    Hypertens Res; 2010 Nov; 33(11):1110-1. PubMed ID: 20861840
    [No Abstract]   [Full Text] [Related]  

  • 14. Prehypertension: is it relevant for nephrologists?
    Kaplan NM
    Clin J Am Soc Nephrol; 2009 Aug; 4(8):1381-3. PubMed ID: 19608711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antihypertensive treatment in the nephropathic patient].
    Andreucci VE; Russo D; d'Amato R; Minutolo R
    Cardiologia; 1996 May; 41 Suppl 1():25-9. PubMed ID: 8831178
    [No Abstract]   [Full Text] [Related]  

  • 16. Pathologic basis and treatment considerations in chronic kidney disease-related hypertension.
    Sica D; Carl D
    Semin Nephrol; 2005 Jul; 25(4):246-51. PubMed ID: 16202697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The complex role of PPARgamma in renal dysfunction in obesity: managing a Janus-faced receptor.
    Dobrian AD
    Vascul Pharmacol; 2006 Jul; 45(1):36-45. PubMed ID: 16716756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Impact of antihypertensive treatment on target organs].
    Fregoso Padilla J
    Arch Cardiol Mex; 2002; 72 Suppl 1():S58-63. PubMed ID: 12001872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Guidelines 2007 of the European Societies of Hypertension and of Cardiology: what has changed?].
    Schmieder RE
    Dtsch Med Wochenschr; 2007 Nov; 132(46):2463-6. PubMed ID: 17987556
    [No Abstract]   [Full Text] [Related]  

  • 20. Changing the timing of antihypertensive therapy to reduce nocturnal blood pressure in CKD: an 8-week uncontrolled trial.
    Minutolo R; Gabbai FB; Borrelli S; Scigliano R; Trucillo P; Baldanza D; Laurino S; Mascia S; Conte G; De Nicola L
    Am J Kidney Dis; 2007 Dec; 50(6):908-17. PubMed ID: 18037091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.